Zhejiang Starry Pharm Co Ltd Net Assets
Zhejiang Starry Pharm Co Ltd net assets. Based on the latest financial reports, Zhejiang Starry Pharm Co Ltd (603520) has net assets worth CN¥2.58 Billion CNY (≈ $377.72 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.27 Billion ≈ $918.15 Million USD) and total liabilities (CN¥3.69 Billion ≈ $540.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Zhejiang Starry Pharm Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.58 Billion |
| % of Total Assets | 41.14% |
| Annual Growth Rate | 16.51% |
| 5-Year Change | 15.79% |
| 10-Year Change | 210.06% |
| Growth Volatility | 28.93 |
Net Assets of Zhejiang Starry Pharm Co Ltd (2011–2025)
Net assets of Zhejiang Starry Pharm Co Ltd from 2011 to 2025. This chart illustrates how Zhejiang Starry Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. See Zhejiang Starry Pharm Co Ltd (603520) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Zhejiang Starry Pharm Co Ltd (2011–2025)
The table below shows the annual net assets of Zhejiang Starry Pharm Co Ltd from 2011 to 2025. For live market cap and overall valuation, see 603520 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.56 Billion ≈ $375.23 Million |
-2.67% |
| 2024-12-31 | CN¥2.63 Billion ≈ $385.50 Million |
+49.78% |
| 2023-12-31 | CN¥1.76 Billion ≈ $257.38 Million |
-0.70% |
| 2022-12-31 | CN¥1.77 Billion ≈ $259.18 Million |
-20.02% |
| 2021-12-31 | CN¥2.21 Billion ≈ $324.06 Million |
+18.76% |
| 2020-12-31 | CN¥1.86 Billion ≈ $272.87 Million |
+81.27% |
| 2019-12-31 | CN¥1.03 Billion ≈ $150.53 Million |
+11.46% |
| 2018-12-31 | CN¥922.96 Million ≈ $135.06 Million |
+5.79% |
| 2017-12-31 | CN¥872.44 Million ≈ $127.67 Million |
+5.49% |
| 2016-12-31 | CN¥827.01 Million ≈ $121.02 Million |
+80.69% |
| 2015-12-31 | CN¥457.70 Million ≈ $66.98 Million |
+5.92% |
| 2014-12-31 | CN¥432.13 Million ≈ $63.23 Million |
+11.92% |
| 2013-12-31 | CN¥386.11 Million ≈ $56.50 Million |
+14.64% |
| 2012-12-31 | CN¥336.81 Million ≈ $49.29 Million |
+11.60% |
| 2011-12-31 | CN¥301.81 Million ≈ $44.16 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Starry Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 661.2% over the analyzed period, indicating profitable operations and earnings retention.
Zhejiang Starry Pharm Co Ltd Net Assets Breakdown (December 2025)
Zhejiang Starry Pharm Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥327.26 Million | 12.79% |
| Other Components | CN¥2.23 Billion | 87.21% |
| Total Equity | CN¥2.56 Billion | 100.00% |
Zhejiang Starry Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Starry Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Yike Food Group Co.Ltd
SHE:301116
|
$524.94 Million |
|
Shenzhen Prince New Materials Co Ltd
SHE:002735
|
$524.95 Million |
|
HCM II Acquisition Corp. Unit
NASDAQ:HONDU
|
$525.00 Million |
|
Guangdong Green Precision Components Co. Ltd.
SHE:300968
|
$525.06 Million |
|
Inox Green Energy Services Limited
NSE:INOXGREEN
|
$524.77 Million |
|
Tibet Weixinkang Medicine Co Ltd
SHG:603676
|
$524.71 Million |
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
$524.68 Million |
|
Assure Tech Hangzhou Co Ltd
SHG:688075
|
$524.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Starry Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,628,155,919 to 2,557,891,801, a change of -70,264,118 (-2.7%).
- Net income of 10,228,417 contributed positively to equity growth.
- Dividend payments of 145,978,759 reduced retained earnings.
- Other comprehensive income decreased equity by 178,999,876.
- Other factors increased equity by 244,486,100.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥10.23 Million | +0.4% |
| Dividends Paid | CN¥145.98 Million | -5.71% |
| Other Comprehensive Income | CN¥-179.00 Million | -7.0% |
| Other Changes | CN¥244.49 Million | +9.56% |
| Total Change | CN¥- | -2.67% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Starry Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.40x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.87x to 1.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥1.19 | CN¥8.18 | x |
| 2012-12-31 | CN¥1.35 | CN¥8.18 | x |
| 2013-12-31 | CN¥1.55 | CN¥8.18 | x |
| 2014-12-31 | CN¥1.70 | CN¥8.18 | x |
| 2015-12-31 | CN¥1.79 | CN¥8.18 | x |
| 2016-12-31 | CN¥2.64 | CN¥8.18 | x |
| 2017-12-31 | CN¥2.59 | CN¥8.18 | x |
| 2018-12-31 | CN¥2.72 | CN¥8.18 | x |
| 2019-12-31 | CN¥3.01 | CN¥8.18 | x |
| 2020-12-31 | CN¥5.46 | CN¥8.18 | x |
| 2021-12-31 | CN¥6.31 | CN¥8.18 | x |
| 2022-12-31 | CN¥5.12 | CN¥8.18 | x |
| 2023-12-31 | CN¥5.15 | CN¥8.18 | x |
| 2024-12-31 | CN¥6.42 | CN¥8.18 | x |
| 2025-12-31 | CN¥5.83 | CN¥8.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Starry Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.42%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 2.41x
- Recent ROE (0.40%) is below the historical average (10.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 22.95% | 13.34% | 0.70x | 2.46x | CN¥38.12 Million |
| 2012 | 10.84% | 6.23% | 0.70x | 2.50x | CN¥2.76 Million |
| 2013 | 16.74% | 9.28% | 0.68x | 2.65x | CN¥25.62 Million |
| 2014 | 16.08% | 10.28% | 0.57x | 2.73x | CN¥25.60 Million |
| 2015 | 15.65% | 9.91% | 0.47x | 3.36x | CN¥24.89 Million |
| 2016 | 9.40% | 11.31% | 0.36x | 2.34x | CN¥-4.89 Million |
| 2017 | 9.70% | 11.69% | 0.35x | 2.35x | CN¥-2.60 Million |
| 2018 | 10.51% | 10.52% | 0.29x | 3.44x | CN¥4.57 Million |
| 2019 | 17.11% | 13.01% | 0.38x | 3.50x | CN¥70.75 Million |
| 2020 | 13.09% | 17.46% | 0.31x | 2.42x | CN¥56.38 Million |
| 2021 | 14.89% | 16.19% | 0.41x | 2.25x | CN¥106.26 Million |
| 2022 | -4.30% | -3.56% | 0.40x | 3.00x | CN¥-252.37 Million |
| 2023 | 2.52% | 2.01% | 0.40x | 3.15x | CN¥-131.03 Million |
| 2024 | -1.87% | -2.09% | 0.39x | 2.30x | CN¥-311.91 Million |
| 2025 | 0.40% | 0.42% | 0.40x | 2.41x | CN¥-245.56 Million |
Industry Comparison
This section compares Zhejiang Starry Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,554,577,785
- Average return on equity (ROE) among peers: 7.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Starry Pharm Co Ltd (603520) | CN¥2.58 Billion | 22.95% | 1.43x | $524.77 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.45 Billion | 1.52% | 1.57x | $485.12 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $576.00 Million | 3.15% | 0.28x | $363.11 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.12 Billion | 13.25% | 0.26x | $4.79 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $623.47 Million | 16.22% | 0.40x | $2.70 Billion |
| Wedge Industrial Co Ltd (000534) | $654.70 Million | 1.92% | 0.87x | $1.28 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $184.00 Million | 12.94% | 0.09x | $14.40 Billion |
| Hainan Haiyao Co Ltd (000566) | $2.20 Billion | -4.84% | 2.35x | $770.77 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $728.20 Million | 3.47% | 0.58x | $275.43 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.67 Billion | 4.59% | 1.27x | $925.00 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $2.34 Billion | 20.86% | 0.40x | $3.01 Billion |
About Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more